Hereditary Cancer in Clinical Practice, 2015 بوليميرازات بولي (ADP - ريبوز)، التي يتم اختصارها باسم PARPs، هي مجموعة من البروتينات المألوفة التي تلعب دورًا مركزيًا في إصلاح الحمض النووي باستخدام مسار إصلاح استئصال القاعدة (BER). هناك حوالي 17 بروتينًا في هذه العائلة منها PARPs النووية الأولية هي PARP -1 و PARP -2 و PARP -3 و tankyrases 1 و 2 (PARP -5a و -5b).
Maheen Anwar +2 more
+6 more sources
PARP Inhibitors in Prostate Cancer [PDF]
Anticancer Research, 2021 Treatment of metastatic prostate cancer has evolved significantly over the past decade. Palliative therapy has, historically, consisted of androgen deprivation, chemotherapy and different radiation therapy approaches. More recently, breakthrough therapy with the use of poly-ADP-ribose polymerase (PARP) inhibitors has led to significant improvement in ...
Kabir, Grewal +2 more
openaire +2 more sources
Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo [PDF]
PeerJ, 2016 Early studies with first-generation poly (ADP-ribose) polymerase (PARP) inhibitors have already indicated some therapeutic potential for sulfur mustard (SM) injuries.
Feng Liu +10 more
doaj +2 more sources
PARP-3 and APLF function together to accelerate nonhomologous end joining [PDF]
, 2010 PARP-3 is a member of the ADP-ribosyl transferase superfamily of unknown function. We show that PARP-3 is stimulated by DNA double-strand breaks (DSBs) in vitro and functions in the same pathway as the poly (ADP-ribose)-binding protein APLF to accelerate
Ahel +59 more
core +1 more source
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. [PDF]
, 2017 Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature.
Berry, Don +20 more
core +2 more sources
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
Cell Reports, 2017 Summary: PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors.
Sergey Karakashev +11 more
doaj +1 more source
The suppression of DNA repair induced by PARP-1 inhibitors rucaparib and olaparib in combination with the radiopharmaceutical 131I-MIBG in noradrenaline transporter-expressing xenograft tumors [PDF]
, 2018 No abstract ...
Gaze, Mark N. +4 more
core +1 more source
Frontiers in Cellular Neuroscience, 2020 Post-stroke inflammation is almost involved in the whole process of stroke pathogenesis, which serves as a prime target for developing new stroke therapies. Despite known sex differences in the incidence and outcome of stroke, few preclinical or clinical
Jian Chen +19 more
doaj +1 more source
Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods [PDF]
PeerJ, 2020 Background Research has shown that Poly-ADP-ribose polymerases 1 (PARP-1) is a potential therapeutic target in the clinical treatment of breast cancer.
Hongye Hu +3 more
doaj +2 more sources
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. [PDF]
PLoS ONE, 2014 AIM OF THE STUDY:To evaluate the frequency of MRE11/RAD50/NBS1 (MRN)-complex loss of protein expression in endometrial cancers (EC) and to determine whether loss of MRE11 renders the cancer cells sensitive to Poly(ADP-ribose) polymerase (PARP)-inhibitory
Romana Koppensteiner +11 more
doaj +1 more source